logo/base Created with Sketch.
See product brochures

FibroScan® Compact 530

The portable non-invasive solution for efficient liver disease management.

Powered by LSM by VCTE® and CAP for liver fibrosis and liver steatosis assessment.

chevron chevron

From cart-based to transportable

FibroScan® Compact 530 is the perfect liver assessment solution for any point-of-care setting.

Portable

Easy to handle and transport. Battery-powered device provided with transport case

Adaptable

Optional roll stand with a lockable drawer for probes, and a keyboard

All Patient Morphologies

Can be used with all probes S+, M+ and XL+

Renowned & Endorsed

Supported by 6,270+ peer reviewed publications and 250+ international guidelines

Patented and Validated

LSM by VCTE® is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness with 5,540+ international peer-reviewed publications.1

CAP is unique patented and validated for liver steatosis assessment2,3 with 2,125+ international peer-reviewed publications.

Learn more
FibroScan® Compact 530

Guided VCTE® : the next generation VCTE® technology

The new Guided VCTE® technology offers intuitive features for faster examinations and simplified scanning.

Learn more about Guided VCTE More information about FibroScan exams

FibroScan® Compact 530 comes with a dedicated support

From installation, to training and local support, we provide you with the highest quality of services.

Learn more

Extend FibroScan® use

Beyond FibroScan®, Echosens develops solutions to optimise the management of liver diseases and assist in guiding treatment decisions.

  • FibroScan® Guided VCTE

    Guided VCTE®

    Seamless liver health assessment for all

    chevron
  • FibroScan® probes

    VCTE® probe

    Optimize measurement accuracy on all patient morphologies

    chevron
  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron
  • FibroScan® Gateway

    FibroScan® Gateway

    Optimize clinical workflows with real-time secure data transmission

    chevron

What our users say

As a clinical researcher, I rely heavily on FibroScan to select the right patient for the right study. Clinical trials in non-alcoholic steatohepatitis typically include patients with specific fibrosis stages. It is thus important to have reliable fibrosis assessment and avoid unnecessary liver biopsies.

Vincent Wong

Hepatologist from Hong Kong

Guided VCTE helps improve operator efficiency and perhaps standardize their performance. We expect that Guided VCTE features will improve the reliability of LSM without prolonging the study duration, even in patients with MASLD.

Dr. Raj Vuppalanchi

Professor of Medicine, Director of Hepatology and Associate Program Director | Indiana University School of Medicine

The ability FibroScan gives to painlessly and quickly locate a liver health risk to a person, which also is one of the world’s biggest silent killers is a no brainer. I have yet to have any person tell me they didn’t want to know, in fact the complete opposite almost everyone alters something in their lives to improve their own and families liver health. 

Louise Campbell

Founder and Medical Director Tawazun Health

Read all testimonials chevron

Request a demo!

Interested in FibroScan®?

Contact us

1.European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
2.Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.
3.Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.

FibroScan® 530 Compact is a class IIa medical devices according to Rule 10 of ANNEX VIII of Regulation EU 2017/745 (CE 0459) and is manufactured by Echosens™. FibroScan® 530 Compact is intended to provide Liver stiffness measurements at a shear wave frequency of 50 Hz and Liver ultrasound attenuation measurements (CAP: Controlled Attenuation Parameter) at 3.5 MHz. FibroScan® 530 Compact is a non-invasive device intended to aid clinical management, diagnosis, and monitoring of patients with confirmed or suspected chronic liver disease, as part of an overall assessment of the liver. FibroScan® device may aid the healthcare professionals in the assessment of liver fibrosis, steatosis, and in determining the likelihood of cirrhosis. FibroScan® device is used, in conjunction with other clinical and laboratory data, during liver assessment in patients with confirmed or suspected chronic liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.

chevron User Guides FibroScan Compact 530